271. Ankylosing spondylitis Clinical trials / Disease details

Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03473665 (ClinicalTrials.gov)	March 1, 2018	13/3/2018	Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis	Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study	Ankylosing Spondylitis;Axial Spondyloarthritis	Drug: Indomethacin;Drug: Diclofenac;Drug: Meloxicam;Drug: Celecoxib	Columbia University	NULL	Terminated	18 Years	N/A	All	9	Phase 4	United States
2	ChiCTR-TRC-11001417	2011-06-01	2011-07-10	clinical study of Mecenchymal Stem Cells transplantation in Ankylosing Spondylitis	clinical study of Mecenchymal Stem Cells transplantation in Ankylosing Spondylitis	Ankylosing Spondylitis (AS)	1:oral salicylazosulfapyridine and indomethacin;2:Mecenchymal Stem Cells(MSC) transplantation ;	Sun Yat-sen Memorial Hospital of Sun Yat-sen University	NULL	Recruiting			Both	1:80;2:80;	I+2 (Phase 1+Phase 2)	China
3	NCT02183168 (ClinicalTrials.gov)	July 2001	4/7/2014	Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis	A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis	Spondylitis, Ankylosing	Drug: Meloxicam suppository;Drug: Meloxicam tablet;Drug: Indomethacin	Boehringer Ingelheim	NULL	Completed	N/A	N/A	Both	192	Phase 3	NULL